352 related articles for article (PubMed ID: 10843450)
1. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Tsujii T
Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
Okada H; Kamidono S; Yoshioka T; Okuyama A; Ozono S; Hirao Y; Okajima E; Yamamoto K; Kishimoto T; Park Y; Kurita T
BJU Int; 2000 Apr; 85(6):676-81. PubMed ID: 10759664
[TBL] [Abstract][Full Text] [Related]
3. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
Lee E; Lee C
Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
[TBL] [Abstract][Full Text] [Related]
4. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
6. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
de Mey C; Michel MC; McEwen J; Moreland T
Eur Urol; 1998; 33(5):481-8. PubMed ID: 9643668
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
Abrams P; Speakman M; Stott M; Arkell D; Pocock R
Br J Urol; 1997 Oct; 80(4):587-96. PubMed ID: 9352698
[TBL] [Abstract][Full Text] [Related]
9. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
[TBL] [Abstract][Full Text] [Related]
10. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
Paick JS; Cho MC; Song SH; Kim SW; Ku JH
J Korean Med Sci; 2008 Jun; 23(3):509-13. PubMed ID: 18583890
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
14. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Chapple CR
Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
[TBL] [Abstract][Full Text] [Related]
15. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
[TBL] [Abstract][Full Text] [Related]
17. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
Lepor H
Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
[TBL] [Abstract][Full Text] [Related]
19. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.
Dong Z; Wang Z; Yang K; Liu Y; Gao W; Chen W
Syst Biol Reprod Med; 2009 Aug; 55(4):129-36. PubMed ID: 19886768
[TBL] [Abstract][Full Text] [Related]
20. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
